Analysing Outcomes After Prostate Cancer Diagnosis and Treatment in Carriers of Rare Germline Mutations
Analysing Outcomes After Prostate Cancer Diagnosis and Treatment in Carriers of Rare Germline Mutation in Cancer Predisposition Genes
About This Trial
- This study is looking at how inherited genes affect how well prostate cancer treatments work and how patients recover.
- It is open to men with prostate cancer who have already had genetic testing to see if they carry certain cancer-related genes.
- This study does not test a new medicine, so participating will not change your regular cancer treatment.
- Instead, researchers will follow your health progress, review your medical records, examine previously stored tumor tissue, and ask for an optional blood or saliva sample.
More Information
- GENPROS aims to analyse the outcomes of patients with rare gene mutations in the cancer predisposition genes, BRCA1, BRCA2, HOXB13, and Lynch Syndrome, after a diagnosis of and treatment for prostate cancer (PCa).
- The study includes a cohort of gene mutation carriers with PCa matched with a control group of men with PCa who are known not to carry a mutation in the same gene.
- Clinical data regarding treatment and patient outcome will be collected retrospectively and prospectively.
- Archived tumour samples will also be collected for tumour profiling.
- A blood or saliva sample will be taken, if the participant consents to this part of the study, for genetic profiling to investigate any association of other inherited factors with PCa outcomes.
- Information obtained from this study will be of critical importance to support clinical trials investigating the most appropriate management of PCa in this group of patients at increased risk of prostate cancer.
Who Can Enroll
- Age Range: 18 years and older
- Gender: Male
- Who This Trial is For: This study is looking at how inherited genes affect how well prostate cancer treatments work and how patients recover.
Study Details
- Start Date: September 2014
- Lead Sponsor: Institute of Cancer Research, United Kingdom
Full Eligibility Criteria
Inclusion Criteria
- Men diagnosed with PCa are eligible if:
- known carriers of germline mutations associated with PCa risk OR
- known non-carriers of mutations in the genes above
Exclusion Criteria
- patients under 18 years of age
- patients who are unable to give informed consent
- patients who cannot be traced (<6 months follow-up) or whose clinical data are not available
- patients whose genetic status is unknown
Treatments
- Other: Observation of treatment outcomes via Questionnaire